參考文獻/References:
[1] Pulte D,Brenner H.Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis[J]. Oncologist, 2010,15(9):994-1001.
[2] Yuan X L,Chen L,Zhang T T,et al.Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-β1[J]. World J Gastroenterol,2011,17(15):2019-2027.
[3] Taube J M,Anders R A,Young G D,et al.Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J]. Sci Transl Med, 2012,4(127):127ra37.
[4] Overacre-Delgoffe A E,Chikina M,Dadey R E,et al.Interferon-γ drives treg fragility to promote anti-tumor immunity[J]. Cell, 2017, 169(6):1130-1141.
[5] Quezada S A, Peggs K S, Simpson T R, et al.Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication[J]. Immunological Reviews, 2011, 241(1):104-118.
[6] Ikushima H,Miyazono K.TGFbeta signalling: a complex web in cancer progression[J]. Nature Reviews Cancer, 2010, 10(6):415-424.
[7] Alhamarneh O, Amarnath S M P, Stafford N D, et al.Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer[J]. Head & Neck,2008, 30(2):251-261.
[8] Wang R, Kozhaya L, Mercer F, et al.Expression of GARP selectively identifies activated human FOXP3t regulatory T cells[J]. Proc Natl Acad Sci U S A,2009,106(32):13439-13444.
[9] Kryczek I, Liu R, Wang G, et al.FOXP3 defines regulatory T cells in human tumor and autoimmune disease[J]. Cancer Res,2009, 69(9):3995-4000.
[10] Tran D Q,Andersson J,Wang R,et al.GARP(LRRC32)is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells[J]. Proc Natl Acad Sci U S A,2009, 106(32):13445-13450.
[11] Wang R,Kozhaya L,Mercer F,et al.Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells[J]. Proceedings of the National Academy of Sciences,2009, 106(32):13439-13444.
[12] Probst-Kepper M,Geffers R,Kroger A,et al.GARP: a key receptor controlling FOXP3 in human regulatory T cells[J]. J Cell Mol Med,2009,13(9B):3343-3357.
[13] Probst-Kepper M, Kr?er A, Garritsen H S, et al.Perspectives on Regulatory T Cell Therapies[J]. Transfus Med Hemother, 2009, 36(5):302-308.
相似文獻/References:
[1]葉 彥,任 飛 綜述 黃慧恒 審校.血清NTx和ICTP在惡性腫瘤骨轉移中的臨床意義[J].福建醫(yī)藥雜志,2021,43(02):153.
[2]劉加夫,張宏英,陳曉紅,等.熒光ROSE在肺惡性腫瘤細胞學診斷中的應用分析[J].福建醫(yī)藥雜志,2024,46(04):6.[doi:10.20148/j.fmj.2024.04.002]
LIU Jiafu,ZHANG Hongying,CHEN Xiaohong,et al.Analysis of fluorescence ROSE in cytological diagnosis of lung malignant tumors[J].FUJIAN MEDICAL JOURNAL,2024,46(03):6.[doi:10.20148/j.fmj.2024.04.002]
[3]林康昵.腫瘤重癥監(jiān)護室膿毒癥患者預后影響因素分析[J].福建醫(yī)藥雜志,2024,46(05):14.[doi:10.20148/j.fmj.2024.05.004]
LIN Kangni.Risk factors for sepsis patients with malignant tumor in intensive care unit[J].FUJIAN MEDICAL JOURNAL,2024,46(03):14.[doi:10.20148/j.fmj.2024.05.004]